Switch from intravenous to subcutaneous infliximab in inflammatory bowel disease: Which consequences from a pharmacokinetic perspective? - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Fundamental & Clinical Pharmacology Année : 2022

Switch from intravenous to subcutaneous infliximab in inflammatory bowel disease: Which consequences from a pharmacokinetic perspective?

Résumé

Meeting Abstract CO-060
Fichier non déposé

Dates et versions

hal-03789365 , version 1 (27-09-2022)

Identifiants

  • HAL Id : hal-03789365 , version 1

Citer

B. Franck, M.C. Verdier, E. Bellissant, G. Bouguen, F. Lemaitre, et al.. Switch from intravenous to subcutaneous infliximab in inflammatory bowel disease: Which consequences from a pharmacokinetic perspective?. Fundamental & Clinical Pharmacology, 2022, 36, pp.43-43. ⟨hal-03789365⟩
17 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More